 Pieris Pharmaceuticals Inc NASDAQ:PIRS shares are trading higher by 57 at 2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. 